Evidence map›Paper›PMID 23242572›Full record

Trial reportInflammopharmacology2013

Safety and efficacy of Curcuma longa extract in the treatment of painful knee osteoarthritis: a randomized placebo-controlled trial.

K Madhu, K Chanda, M J Saji

3 registry-linked trialsAbstract readRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in Inflammopharmacology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 58 papers, 21 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
58citing papers in PubMed, 21 pooled it
4.3field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04269876 naterminatednot on this mapstarted 2019, after this paper: background citation

A Double-blind, Randomized, Placebo-controlled Study to Evaluate the Effects of a Specialized Pro-Resolving Mediator Formulation on Inflammation in Individuals Who Are Overweight to Mildly Obese and Otherwise Generally Healthy

TypeinterventionalSponsorSupplement Formulators, Inc.Ran2019 to 2021Enrolled8ConditionsInflammation, Inflammatory ResponseArmsMarine Lipid Oil Concentrate, Dietary Supplement, Placebo
NCT04819646 nacompletednot on this mapstarted 2021, after this paper: background citation

An Open-label, Single-arm Study to Evaluate the Effects of a Marine Lipid Oil Concentrate Formulation on Inflammation/Discomfort in Individuals Who Are Generally Healthy

TypeinterventionalSponsorSupplement Formulators, Inc.Ran2021 to 2021Enrolled31ConditionsInflammationArmsMarine Lipid Oil Concentrate Formulation, Dietary Supplement
NCT06105840 phase1 / phase2unknown statusnot on this mapstarted 2023, after this paper: background citation

Effect of Combination of Curcuminoid Standardized Turmeric Extract With Acupressure on Inflammatory Markers, Endorphins and Quality of Life in Elderly People With Osteoarthritis Genu

TypeinterventionalSponsorGadjah Mada UniversityRan2023 to 2023Enrolled70ConditionsOsteoarthritis, KneeArmsAcupressure and Standardized Curcuminoid from Turmeric Extract, Sham Acupressure and Placebo
3 · Its place in the literature

Who cites it

58 citing papers in PubMed, 21 syntheses or guidelines pooled it, 152 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. The Search for Drugs Derived from Natural Products forCurrent topics in medicinal chemistry · 2024
    Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Efficacy and Safety of Curcumin andFrontiers in immunology · 2022
    Pooled it
  12. Pooled it
  13. Pooled it
  14. Pooled it
  15. Pooled it
  16. Guideline
  17. Pooled it
  18. Pooled it
  19. Pooled it
  20. Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 2 countries.

K MadhuDivision of Clinical Pharmacology, St. John's Medical College, Bangalore 560034, India.
K Chanda
M J Saji
St. John's College of Nursing · USSt.John's Medical College Hospital · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Curcuma longa Linn. is widely used for the treatment of disorders associated with inflammation and was evaluated for its safety and efficacy in the treatment of painful knee osteoarthritis (OA). This was a randomized, single blind, placebo-controlled trial. Total of 120 patients (37 males and 83 females) with primary knee OA received either placebo (400 mg twice daily) or NR-INF-02 (500 mg twice daily) or glucosamine sulphate (GS) (750 mg twice daily) alone or combination of NR-INF-02 and GS for 42 days. The efficacy was assessed during treatment period, on day 21 and day 42. The decrease in severity of pain symptom and function of affected knee as primary efficacy outcome measure was assessed by Visual Analog Scale (VAS) and Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) scale, respectively. The clinical examination of affected joint was measured by an orthopaedic specialist and using a Clinician Global Impression Change (CGIC) scale. The analysis of post-treatment scores following administration of NR-INF-02 using VAS, WOMAC, and CGIC at each clinical visit showed significant decrease (p < 0.05) compared to placebo. NR-INF-02 treated group showed a significant (p < 0.01) decrease in use of rescue medication, along with clinical and subjective improvement compared to placebo. The tolerability and acceptability profile of NR-INF-02 was better during the trial period. The study demonstrates safety and efficacy of NR-INF-02 as a useful treatment option for patients with primary painful knee OA.

Indexed as

Anti-Inflammatory Agents, Non-SteroidalCurcumaFemaleGlucosamineHumansKnee JointMaleMiddle AgedOsteoarthritis, KneePainPain MeasurementPlant ExtractsSeverity of Illness IndexSingle-Blind MethodTreatment OutcomeAnti-Inflammatory Agents, Non-SteroidalGlucosaminePlant Extracts

Identifiers

PMID23242572
OpenAlexW2064044450

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.